

BLA 761055/S-021  
BLA 761055/S-027  
BLA 761055/S-033

## SUPPLEMENT APPROVAL

Regeneron Pharmaceuticals, Inc.  
Attention: Elisa Babilonia, PhD  
Senior Director, Regulatory Affairs  
777 Old Saw Mill River Rd  
Tarrytown, NY 10579

Dear Dr. Babilonia:

Please refer to your supplemental biologics license applications (sBLAs) S-021, dated and received February 19, 2020, S-027, dated and received June 9, 2020, S-033, dated and received January 29, 2021, and your amendments, submitted under section 351(a) of the Public Health Service Act for DUPIXENT (dupilumab) injection, for subcutaneous use.

The Prior Approval supplemental biologics applications provide for the following changes to the DUPIXENT label:

- S-021: Addition of angioedema to the postmarketing adverse reactions section.
- S-027: Addition of information related to the conjunctivitis and keratitis adverse drug reaction based on emergent postmarketing data.

The “Changes Being Effected” supplemental biologics application provides for the following change to the DUPIXENT label:

- S-033: Addition of facial skin reactions to the postmarketing adverse reactions section.

Additional updates to the vaccination information in the DUPIXENT label and other labeling updates in accordance with current Agency recommendations were included in these supplemental biologics license applications.

### **APPROVAL & LABELING**

We have completed our review of these applications, as amended. The applications are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,<sup>1</sup> that is identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert) and include the labeling changes proposed in any pending “Changes Being Effectuated” (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effectuated” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

BLA 761055/S-021  
BLA 761055/S-027  
BLA 761055/S-033  
Page 3

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 601.12(a)(4)]. The revisions to your promotional materials should include prominent disclosure of the important new safety information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 601.12(a)(4).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Matthew White, Senior Regulatory Project Manager, at 301-796-4997.

Sincerely,

*{See appended electronic signature page}*

Tatiana Oussova, MD, MPH  
Deputy Director for Safety  
Division of Dermatology and Dentistry  
Office of Immunology and Inflammation  
Office of New Drugs  
Center for Drug Evaluation and Research

### **ENCLOSURE(S):**

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert

**U.S. Food and Drug Administration**  
Silver Spring, MD 20993  
[www.fda.gov](http://www.fda.gov)

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

TATIANA OUSSOVA  
12/22/2021 10:37:15 AM